PROLENSA

This brand name is authorized in Canada, United States

Active ingredients

The drug PROLENSA contains one active pharmaceutical ingredient (API):

1 Bromfenac
UNII 8ECV571Y37 - BROMFENAC SODIUM

Bromfenac is a topical, nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. It is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2. The most commonly reported adverse reactions in 3 to 8% of patients were anterior chamber inflammation, foreign body sensation, eye pain, photophobia and vision blurred.

Read about Bromfenac

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
PROLENSA Ophthalmic solution FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
S01BC11 S Sensory organs → S01 Ophthalmologicals → S01B Antiinflammatory agents → S01BC Antiinflammatory agents, non-steroids
Discover more medicines within S01BC11

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: CA Health Products and Food Branch Identifier(s): 02439123
Country: US FDA, National Drug Code Identifier(s): 24208-602

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.